NCT02705300View on ClinicalTrials.gov

Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 6, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

March 27, 2024

Conditions
Colorectal Cancer
Interventions
DRUG

Irinotecan 165 mg/m2 iv

Max. 4 months

DRUG

Oxaliplatin 85 mg/m2 iv

Max. 4 months

DRUG

Calcium folinate 200 mg/m2 iv

Max. 6 months

DRUG

5-fluorouracil 3200 mg/m2

Max. 6 months

DIETARY_SUPPLEMENT

Tocotrienol

Max. 2 years or at the discretion of the investigator

DRUG

Placebo

Max. 2 years or at the discretion of the investigator

Trial Locations (1)

DK-7100

Department of Oncology, Vejle Hospital, Vejle

All Listed Sponsors
lead

Vejle Hospital

OTHER

NCT02705300 - Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter